VYNE Therapeutics (VYNE) announced completion of enrollment in the Phase 2b trial evaluating VYN201 gel for the treatment of nonsegmental vitiligo. Top-line data from the 24-week vehicle-controlled treatment period are expected in mid-2025. Additionally, the United States Adopted Names Council has adopted “repibresib” as the non-proprietary name for the new chemical entity in VYN201.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYNE:
- H.C. Wainwright says VYNE’s VYN202 becomes ‘pick of the crop’ after MAD data
- VYNE Therapeutics announces results from MAD portion of Phase 1a SAD/MAD trial
- VYNE Therapeutics Sees Strong Shareholder Support for Growth
- VYNE Therapeutics initiated with a Buy at BTIG on I&I potential
- VYNE Therapeutics initiated with a Buy at BTIG